Umbiko wokuqala wokutholwe ocwaningweni lomtholampilo i-NCT02735707 okubikwe ku-preprint uphakamisa ukuthi i-Tocilizumab kanye ne-Sarilumab, abaphikisi be-interleukin-6 receptor bayasebenza ekwelapheni iziguli ezigula kakhulu ze-COVID-19 kanye nokwenza ngcono ukusinda..
Kakhulu Iziguli ezigulayo ze-COVID-19 ezithola ukwesekwa kokunakekelwa okuqinile zasabela kahle ekwelashweni ngama-IL-6 receptor antagonists, i-tocilizumab ne-sarilumab. Isibhedlela yangenyama kwaba ngu-28.0 % we-tocilizumab, u-22.2% we-sarilumab kanye no-35.8% wokulawula okusho ukuthi izinga lokusinda lithuthukisiwe ukusekela ukusebenza kangcono kwale mithi ehloselwe kabusha. (1)
Izidakamizwa i-tocilizumab (i-antibody monoclonal humanized ngokumelene ne-IL-6 receptor) kanye ne-sarilumab (umuntu i-antibody eyodwa ngokumelene ne-IL-6 receptor) zivame ukusetshenziswa njengama-immunosuppressants ekwelapheni i-rheumatoid arthritis.
Esimweni sezulu samanje Covid-19 ubhubhane lapho izinga lokufa kwabantu kanye nokutheleleka liphezulu, kuyajabulisa kakhulu ukuqaphela ukuthi le mithi emibili esetshenziswe kabusha inciphise kakhulu ukuhlala kweziguli ze-COVID-19 ewodini labagula kakhulu esibhedlela futhi yehlisa izinga lokufa cishe ngekota. Lokhu ngokuyisisekelo kusho ukufa okumbalwa kanye nokuhlala isikhathi esifushane ekunakekelweni okubucayi, ngaleyo ndlela kugcinwe amandla ezibhedlela ukubhekana nalolu bhubhane.
Lolu cwaningo lomtholampilo luxhaswe yi-EU esekela i-REMAP-CAP nge-Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE) iphrojekthi. Ukwesekwa okwengeziwe kuvela kuphrojekthi ehlobene ye-Rapid European SARS-CoV-2 Emergency Research (RECOVER) (2).
***
Imithombo:
- Abaphenyi be-REMAP-CAP, Gordon AC., 2020. I-Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 - Umbiko wokuqala. Ukuphrinta ngaphambili: MedRxiv. Kuthunyelwe ngoJanuwari 07, 2021. DOI: https://doi.org/10.1101/2021.01.07.21249390
- I-European Commission, 2021. Izindaba - Isivivinyo somtholampilo esixhaswe yi-EU sithola ukwelashwa okusha kusebenza ngempumelelo ngokumelene ne-COVID-19. Ishicilelwe ngomhla ka-8 Januwari 2021. Itholakala ku-inthanethi https://ec.europa.eu/info/news/eu-funded-clinical-trial-finds-new-treatments-be-effective-against-covid-19-2021-jan-08_en&pk_campaign=rtd_news
- Isivivinyo Somtholampilo I-NCT02735707: I-Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (REMP-CAP) Itholakala ku-inthanethi ku- https://clinicaltrials.gov/ct2/show/NCT02735707?term=NCT02735707&cond=Covid19&draw=2&rank=1#contacts
***
